Apimeds Pharmaceuticals US, Inc

of this Current Report on Form 8-K in the section titled “ Changes to the Board of Directors and Management ” is incorporated into this Item 5.02 by reference.

. Completion of Acquisition or Disposition of Assets. The disclosure set forth above in Item 1.01 of this Current Report on Form 8-K is incorporated into this I

by reference. Item 3.02 Unregistered Sales of Equity Securities. The disclosure set forth above in Item 1.01 of this Current Report on Form 8-K in the sections

by reference. The issuance of the Merger Consideration and the offer, sale and issuance of the Notes have not been registered under the Securities Act of 1933,

. Changes in Control of Registrant. The disclosure set forth above in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 2.01 by refere

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The disclosur

. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On December 1, 2025, the Acquiror caused to be filed with the DE SOS, the Certificat

by reference. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwis

(b) as an amendment to this Current Report on Form 8-K no later than 71 calendar days after the required filing for this Current Report on Form 8-K. 11 (d) Exhi